Vanguard Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.91M Buy
42,880
+4,270
+11% +$929K ﹤0.01% 816
2026
Q2
$9.45M Buy
38,610
+4,730
+14% +$1.03M 0.01% 743
2026
Q1
$5.73M Buy
+33,880
New +$5.85M ﹤0.01% 873

Other funds holding AXSM

Vanguard Asset Management's AXSM Position: Q3 2026 in Review

Vanguard Asset Management increased its Axsome Therapeutics (AXSM) stake by 11% in Q3 2026, buying an estimated $929K and bringing the position to 42,880 shares worth $7.91M. The position accounts for ﹤0.01% of the portfolio, ranked #816.

Vanguard Asset Management first reported a position in AXSM in Q1 2026 and has held it in 3 quarters since. The position peaked at $9.45M in Q2 2026. 465 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Vanguard Asset Management held 42,880 shares of Axsome Therapeutics worth $7.91M as of Q3 2026.
  • Vanguard Asset Management bought 4,270 Axsome Therapeutics shares in Q3 2026, an estimated $929K.
  • Axsome Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #816 holding.
  • Vanguard Asset Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Asset Management's Axsome Therapeutics position peaked at $9.45M in Q2 2026.
  • 465 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.